Capricor Therapeutics Awaits FDA Review for Duchenne Therapy

Published 1 hours agoCAPR

Capricor Therapeutics Awaits FDA Review for Duchenne Therapy

Capricor Therapeutics is currently waiting for an important decision from the FDA regarding their Duchenne muscular dystrophy treatment, deramiocel. As of March 4, 2025, the FDA has granted Priority Review status to Capricor's Biologics License Application for deramiocel, which sets the stage for a potential decision by August 31, 2025. This cell therapy focuses on treating cardiomyopathy, a common, severe complication in DMD patients.

Key clinical trial data has shown that deramiocel could significantly impact the progression of DMD-related cardiac issues. The company has also secured Orphan Drug Designation in both the United States and Europe, along with other crucial regulatory statuses that highlight the therapy's potential impact in these territories. Capricor has aligned with Nippon Shinyaku for future commercialization in the U.S. and Japan, pending regulatory approvals.

Market-wise, Capricor's stock performance recently faced a setback. By the latest report, shares were valued at $10.50, representing a $1.36 drop from previous levels, as noted by Reuters. Despite the fluctuations, ongoing developments with deramiocel's regulatory progress remain a core focus for investors and stakeholders.

Share this article

Twitter Facebook LinkedIn

Recent Articles

Tyson Foods Faces Stock Drop Amid Mixed Financial Results

Tyson Foods Faces Stock Drop Amid Mixed Financial Results

14 minutes agoTSN

Tyson Foods' stock took a dramatic hit, declining by over 9% following the company's latest financial results. Although the food giant surpassed earnings expectations with a reported 92 cents per share compared to analysts' predictions of 82 cents, it fell short on revenue. Total revenue came in at $13.07 billion, slightly under the estimated $13.14 billion. Despite these setbacks, Tyson's chicken division showed impressive performance, with income doubling to $312 million. This was propelled by strong consumer demand and a 1.1% decrease in average chicken prices. In contrast, its beef segment struggled, posting an operating loss of $149 million. This was due to constrained cattle supplies and an 8.2% rise in beef prices, which led to decreased consumer demand, Reuters reported. Amid these challenges, Tyson Foods maintains optimism for its chicken segment and has reaffirmed its annual revenue projections. The company is also taking proactive legal steps, increasing its legal contingency accrual by $250 million in response to ongoing pork price-fixing allegations. These moves demonstrate its strategy to navigate current hurdles and strengthen its market position.

Apple Launches First Bond Offering in Two Years Amid Active Market

Apple Launches First Bond Offering in Two Years Amid Active Market

1 hours agoAAPL

Apple Inc. has announced its return to the bond market with its first offering in two years, stirring considerable interest in a week characterized by heavy bond issuance. This four-part bond plans to raise between $5 billion and $6 billion, with proceeds earmarked for stock repurchases, debt repayment, and general corporate purposes. The move comes as Apple faces $8 billion in debt maturing from May to November, making the timing of this issuance particularly relevant. The launch of Apple's bond offering coincides with an eventful week for the investment-grade primary market, anticipated to see around $35 billion in issuance from nine different entities. According to CreditSights, Apple's contribution adds notable volume to this busy period as the company seeks to manage its maturing obligations effectively. Reuters reported that this surge in bond supply is happening alongside recent improvements in credit spreads, which had narrowed following the easing of tensions after President Donald Trump's tariff announcement. This market backdrop provides a conducive environment for Apple's strategic financial maneuvers as it looks to leverage improved credit conditions.

Okta Advances in Identity Security with AI Integration

Okta Advances in Identity Security with AI Integration

1 hours agoOKTA

Okta is making strategic moves to become a front-runner in identity security amidst the growth of generative AI. In October 2023, the company launched Okta AI, which integrates AI capabilities throughout its platforms to bolster security policies, governance, and threat detection. This significant update aims to enhance real-time identity actions that improve security, user engagement, and streamline application development. The company has introduced new security tools like Identity Threat Protection for real-time identification and response to identity-based threats. Another addition is the Extended Device Single Sign-On, aiming to tie user identities to their devices as a measure against phishing attacks. In a report from Reuters, Okta’s expanded partnership with Nametag includes the addition of Deepfake Defense™, a cutting-edge identity verification engine aimed at preventing AI-fueled impersonation threats. Okta's strategic initiatives include setting industry standards such as the Interoperability Profile for Secure Identity in the Enterprise (IPSIE), showcasing its commitment to leadership in AI security. These efforts place Okta at the forefront of securing identities in the dynamic landscape shaped by artificial intelligence.

Capricor Therapeutics Awaits FDA Review for Duchenne Therapy

Capricor Therapeutics Awaits FDA Review for Duchenne Therapy

1 hours agoCAPR

Capricor Therapeutics is currently waiting for an important decision from the FDA regarding their Duchenne muscular dystrophy treatment, deramiocel. As of March 4, 2025, the FDA has granted Priority Review status to Capricor's Biologics License Application for deramiocel, which sets the stage for a potential decision by August 31, 2025. This cell therapy focuses on treating cardiomyopathy, a common, severe complication in DMD patients. Key clinical trial data has shown that deramiocel could significantly impact the progression of DMD-related cardiac issues. The company has also secured Orphan Drug Designation in both the United States and Europe, along with other crucial regulatory statuses that highlight the therapy's potential impact in these territories. Capricor has aligned with Nippon Shinyaku for future commercialization in the U.S. and Japan, pending regulatory approvals. Market-wise, Capricor's stock performance recently faced a setback. By the latest report, shares were valued at $10.50, representing a $1.36 drop from previous levels, as noted by Reuters. Despite the fluctuations, ongoing developments with deramiocel's regulatory progress remain a core focus for investors and stakeholders.